Health Care·NASDAQ·All covered stocks

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Stock News & Analysis

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 3 articles on AMPH since May 7, 2026, most recently "Amphastar (NASDAQ: AMPH) Q2 Adjusted EPS of $0.91 Beats $0.63 Estimate, But GAAP Net Income Slips" on Thursday, August 6, 2026. Coverage to date spans Earnings Report and Health Care, tracking AMPH's earnings, analyst activity, and material corporate events. New coverage is added each trading day.

Price

$23.04

Today

+0.48%

Mkt Cap

$980M

P/E

12.4x

52W High

$29.52

52W Low

$16.65

Data via Finnhub · refreshes hourly · not financial advice

AMPH Coverage -- 3 Articles

Earnings Report·Thursday, August 6, 2026

Amphastar (NASDAQ: AMPH) Q2 Adjusted EPS of $0.91 Beats $0.63 Estimate, But GAAP Net Income Slips

Adjusted EPS of $0.91 crushed the $0.63 estimate, yet GAAP net income fell 2.2% as SG&A and G&A each jumped 30% YoY.

4 min readRead article

Important Legal Disclaimer

This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.

Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.

Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.